By Benjamin Horney (December 20, 2016, 4:26 PM EST) -- French pharmaceutical company Sanofi SA is making progress in its attempt to buy Swiss biotech Actelion Ltd., Reuters reported on Tuesday, even though some investors fear Actelion's chief executive officer and founder might get cold feet and choose not to sell. According to the report, the two sides are so close to a deal that if Actelion were to opt out at this point, it could cause serious problems for the company, with investors potentially "demanding the overthrow of its board." Reports last week said that the two companies were in talks, and that Johnson & Johnson rescinded an offer it previously made for Actelion. Reports have said that Sanofi could wind up inking a deal that values Actelion at up to $30 billion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
